Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Yabe

Showing results (251-260 of 253) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 253 results.
Cancer Research|June 28, 2020
Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine TumorsYuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, et al.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
Pageof 26

Showing results (251-260 of 253) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 253 results.
Cancer Research|June 28, 2020
Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine TumorsYuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, et al.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
Pageof 26